Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers.

MLA

Skorupan, Nebojsa, et al. “Tofacitinib to Prevent Anti-Drug Antibody Formation against LMB-100 Immunotoxin in Patients with Advanced Mesothelin-Expressing Cancers.” Frontiers in Oncology, vol. 14, Apr. 2024, p. 1386190. EBSCOhost, https://doi.org/10.3389/fonc.2024.1386190.

APA

Skorupan, N., Peer, C. J., Zhang, X., Choo-Wosoba, H., Ahmad, M. I., Lee, M.-J., Rastogi, S., Sato, N., Yu, Y., Pegna, G. J., Steinberg, S. M., Kalsi, S. S., Cao, L., Figg, W. D., Trepel, J. B., Pastan, I., FitzGerald, D., & Alewine, C. (2024). Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers. Frontiers in Oncology, 14, 1386190. https://doi.org/10.3389/fonc.2024.1386190

Chicago

Skorupan, Nebojsa, Cody J Peer, Xianyu Zhang, Hyoyoung Choo-Wosoba, Mehwish I Ahmad, Min-Jung Lee, Shraddha Rastogi, et al. 2024. “Tofacitinib to Prevent Anti-Drug Antibody Formation against LMB-100 Immunotoxin in Patients with Advanced Mesothelin-Expressing Cancers.” Frontiers in Oncology 14 (April): 1386190. doi:10.3389/fonc.2024.1386190.